Latest updates from EU: Develop Once, Access Europe: The Power of Joint Clinical Assessment (JCA)
At Parexel, we're committed to guiding you through the evolving European regulatory landscape. Join us as we delve into the Joint Clinical Assessment (JCA) process and its profound impact on market access strategies.
Key Topics:
- Introduction to JCA • Understand the fundamentals and implications of JCA • Learn how JCA is reshaping the European regulatory landscape
- HTA-proofing Development • Discover how JCA impacts early trial design • Strategies for aligning clinical development with HTA requirements
- Beyond Efficacy: Integrating Value into EMA Assessment • Learn techniques for incorporating value propositions into regulatory submissions • Understand how to balance efficacy data with value demonstrations
- Bridging the Gap to HTA Acceptance • Explore strategies to align regulatory approvals with HTA expectations • Learn how JCA can streamline the path from EMA approval to HTA acceptance
Related Insights
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to global: Designing data that travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Blog
Accelerating first-in-human studies: Why the FDA’s Expedited IND pilot signals a new era for early development
Jul 6, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
Related Insights
Article
A shifting European policy landscape: How will Europe’s new incentives reshape rare-disease clinical development?
Oct 26, 2026
Article
China’s rare disease drug development landscape: Overview and insights for global biopharmaceutical companies
Oct 22, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to global: Designing data that travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Blog
Accelerating first-in-human studies: Why the FDA’s Expedited IND pilot signals a new era for early development
Jul 6, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026